Loading…
Viridian Therapeutics, Inc. is projected to rise to $24.75 by 2027, a +24% move from its current price of $19.90. VRDN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $19.46 | $19.91 | $20.38 | +0.07% |
| Aug 2 | $19.28 | $19.93 | $20.59 | +0.14% |
| Aug 3 | $19.15 | $19.94 | $20.76 | +0.20% |
| Aug 4 | $19.05 | $19.95 | $20.90 | +0.27% |
| Aug 5 | $18.96 | $19.97 | $21.03 | +0.34% |
| Aug 6 | $18.88 | $19.98 | $21.15 | +0.41% |
| Aug 7 | $18.80 | $20.00 | $21.26 | +0.48% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.80 | $20.00 | $21.26 | +0.48% |
| Week 2 | $18.42 | $20.09 | $21.92 | +0.96% |
| Week 3 | $18.15 | $20.19 | $22.45 | +1.44% |
| Week 4 | $17.94 | $20.28 | $22.94 | +1.93% |
| Week 5 | $17.76 | $20.38 | $23.38 | +2.42% |
| Week 6 | $17.62 | $20.48 | $23.81 | +2.91% |
| Week 7 | $17.49 | $20.58 | $24.21 | +3.40% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R.
The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc.
and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Viridian Therapeutics, Inc. VRDN is a healthcare company focused on developing treatments for serious and rare diseases, with a portfolio centered on IGF-1R therapies for thyroid eye disease and related conditions. It maintains a pipeline that includes therapeutic candidates such as Veligrotrug and Elegrobart, as well as FcRn inhibitors VRDN-006 and VRDN-008.
The organization has a history dating back to its incorporation in 2010 and is headquartered in Waltham, Massachusetts. The stock trades in the public markets with a current price of $19.70 and a market capitalization near $2.18B, and it holds a market position reflected by a rank of 1876. The pricing and technical outlook reflect a nuanced near-term picture and a longer-term growth trajectory as shown in the year-by-year forecast.
A major floor 33.2% below — a decisive break under it would weaken the trend.
The nearest floor, 16.4% below — buyers have tended to step in here.
Price is pressing into resistance (2.9% away) — a breakout level to watch.
A major ceiling 42.5% above — clearing it would confirm fresh momentum.
Key VRDN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VRDN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $19.65 | Buy | $19.66 | Buy |
| MA 10 | $19.25 | Buy | $19.43 | Buy |
| MA 20 | $19.31 | Buy | $19.07 | Buy |
| MA 50 | $17.89 | Buy | $18.57 | Buy |
| MA 100 | $18.65 | Buy | $19.59 | Buy |
| MA 200 | $24.00 | Sell | $20.87 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.33 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 80.82 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 4.30 | Buy |
| Bollinger %B (20,2) | 0.74 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.40 | Buy |
| Awesome (5,34) | 1.19 | Buy |
| Ultimate (7,14,28) | 70.90 | Sell |
| Momentum (10) | 1.87 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 19.94 | Sell |
| ADX (14) | 16.46 | Neutral |
| ATR (14) | 0.36 | Info |
The near-term technical picture is neutral. The RSI14 sits at 60, indicating a balanced momentum. The stock’s short-term moving averages show a 50-day average of $17.67 and a 200-day average of $24.04, framing possible support and resistance levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.30 | $19.90 | $27.30 | 0% | Neutral | |
| $20.00 | $24.75 | $32.20 | +24% | Bullish | |
| $23.17 | $29.35 | $39.46 | +48% | Bullish | |
| $27.67 | $35.73 | $49.28 | +80% | Bullish | |
| $29.11 | $38.25 | $53.90 | +92% | Bullish | |
| $30.25 | $40.37 | $57.95 | +103% | Bullish | |
| $31.59 | $42.76 | $62.44 | +115% | Bullish | |
| $33.34 | $45.74 | $67.82 | +130% | Bullish | |
| $39.13 | $54.38 | $81.76 | +173% | Bullish | |
| $44.52 | $62.61 | $95.38 | +215% | Bullish | |
| $54.86 | $81.48 | $131.15 | +309% | Bullish | |
| $115.10 | $187.46 | $327.14 | +842% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $13.30 | $19.90 | $23.19 | +0.00% |
| August 2026 | $17.35 | $20.30 | $24.26 | +2.01% |
| September 2026 | $17.97 | $21.18 | $25.60 | +4.32% |
| October 2026 | $18.05 | $21.39 | $26.08 | +0.99% |
| November 2026 | $17.97 | $21.39 | $26.29 | +0.04% |
| December 2026 | $18.46 | $22.08 | $27.30 | +3.19% |
Click any year to see its month-by-month VRDN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, VRDN is projected to trade between $13.30 and $27.30, averaging $19.90 — a potential gain of 0% from today's $19.90. A consolidation phase looks the most probable path here.
Viridian Therapeutics, Inc.'s 2027 outlook centres on $24.75, within a $20.00 to $32.20 range. That is up +24% on the projected 2026 average. That marks a +24% change versus current levels. Momentum favours further upside here.
By 2028, VRDN could reach as high as $39.46, with a base case around $29.35 and support toward $23.17 — roughly +48% from $19.90. Buyers look set to stay in control over this stretch.
Expect VRDN to range from $27.67 to $49.28 through 2029. The $35.73 average target implies a +80% move from current prices. That is up +22% on the projected 2028 average. Momentum favours further upside here.
The VRDN price prediction for 2030 points to an average of $38.25 (low $29.11, high $53.90) — a potential gain of +92% on today's $19.90. Buyers look set to stay in control over this stretch.
In 2031, VRDN is projected to trade between $30.25 and $57.95, averaging $40.37 — a potential gain of +103% from today's $19.90. That is up +6% on the projected 2030 average. Momentum favours further upside here.
Viridian Therapeutics, Inc.'s 2032 outlook centres on $42.76, within a $31.59 to $62.44 range. That is up +6% on the projected 2031 average. That marks a +115% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, VRDN could reach as high as $67.82, with a base case around $45.74 and support toward $33.34 — roughly +130% from $19.90. Momentum favours further upside here.
Expect VRDN to range from $39.13 to $81.76 through 2034. The $54.38 average target implies a +173% move from current prices. That is up +19% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The VRDN price prediction for 2035 points to an average of $62.61 (low $44.52, high $95.38) — a potential gain of +215% on today's $19.90. Momentum favours further upside here.
In 2040, VRDN is projected to trade between $54.86 and $131.15, averaging $81.48 — a potential gain of +309% from today's $19.90. That is up +30% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Viridian Therapeutics, Inc.'s 2050 outlook centres on $187.46, within a $115.10 to $327.14 range. That is up +130% on the projected 2040 average. That marks a +842% change versus current levels. Momentum favours further upside here.
Investing $1,000 in VRDN today (≈ 50.251256 VRDN) could be worth
$9,420.04
+$8,420.04 (+842%) by 2050 · US Dollar
Based on the average projected VRDN price of $187.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VRDNwould be worth at today's price.
$1,000 invested in VRDN on Jul 30, 2025 (≈ 56.179778 VRDN) would be worth
$1,117.98
+$117.98 (+11.8%) today · 1.12× · US Dollar
Based on a VRDN entry price of $17.8 vs. today's $19.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.26 | $1,033.23 | +3.3% |
| 1 month ago | $18.37 | $1,083.29 | +8.3% |
| 3 months ago | $13.42 | $1,482.86 | +48.3% |
| 6 months ago | $33 | $603.03 | -39.7% |
| 1 year ago | $17.8 | $1,117.98 | +11.8% |
| All time (5.0y) ago | $15.02 | $1,324.9 | +32.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VRDN forecast.
Our base-case forecast reaches $40.00 around 2031.
Implied market cap at $40.00: $4.42B
The multi-year forecast shows a bullish trajectory after 2026. In 2027 the average price is projected at $24.22 with a 23% ROI and a bullish sentiment. By 2028 the average is $28.72 with a 45.8% ROI, followed by 2029 at $35.32 with a 79.3% ROI.
The 2030 forecast calls for an average of $37.28 and an 89.2% ROI, rising further to $38.92 in 2031 and $41.07 in 2032 with continued bullish sentiment through 2033 ($43.33, 119.9% ROI) and 2034 ($51.76, 162.7% ROI). The long-range outlook remains strong with 2040 showing an average of $75.85 and a 285.1% ROI, and 2050 at an average of $176.33 with a 795.1% ROI, underscoring substantial upside potential under the projected path while noting that these are estimates and not guarantees. Drivers and risks are not detailed beyond the year-by-year numbers, but the figures illustrate a consistently rising price path alongside increasing ROI and bullish sentiment through 2050.
Tap a question to reveal the answer.
According to the forecast, VRDN could have an average price of $37.28 in 2030, with a min of $27.91 and a max of $53.58 and an estimated ROI of 89.2%.
The forecast shows bullish sentiment from 2027 onward with rising averages and positive ROI (2027 avg $24.22, ROI 23%; 2028 avg $28.72, ROI 45.8%; 2029 avg $35.32, ROI 79.3%; 2030 avg $37.28, ROI 89.2%). It also notes a neutral view in 2026 with an average of $19.70 and ROI of 0%.
Yes. The max forecast reaches $53.58 in 2030 and climbs to $125.96 by 2040 and $319.40 by 2050, with the 2050 average at $176.33 and a max of $319.40, indicating the potential to exceed $100 on the upside trend.
The 30-day range is $16.61 to $23.36. The sentiment is NEUTRAL, with RSI 14 at 60, SMA50 at $17.67, SMA200 at $24.04, support at $15.98, and resistance at $20.47.
The current price is $19.70 and the market capitalization is $2.18B, with a rank of 1876.
Viridian Therapeutics, Inc. Community Discussion
0Share your Viridian Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.